



AffiniSol™


Pharma & Food Solutions

---

**AFFINISOL™**

Solving the Insoluble with Dow

---



---

## Solving the Insoluble With DOW

---

High throughput screening methods are frequently identifying physically complex new chemical entities (NCEs) that are lipophilic with higher molecular weights. This has resulted in approximately 40% of NCEs in drug development pipelines having poor water solubility. More recent reports indicate this number has grown substantially to nearly 90%\*. Many of these Active Pharmaceutical Ingredients (APIs) fall into the Biopharmaceutics Classification System (BCS) Class II displaying low solubility but having high biological permeability.

For such APIs the low aqueous solubility severely limits the compound's oral bioavailability and thus commercial viability. Therefore, formulation scientists are consistently in need of functional excipients and enabling technologies capable of increasing the API solubility in order to achieve therapeutically relevant and reproducible concentrations within the blood and thus a successful drug product.

\* Stokbroekx Sigrid: Formulation Effects on Drug Absorption. Bioavailability and Bioequivalence: Focus on Physiological Factors and Variability. EUFEPS and COST B25 Conference; 2007



### **Excipient & Material Science Expertise Combined with State of the Art Technologies**

Dow, through its Dow Pharma & Food Solutions (DP&FS) business unit, is committed to addressing the pipeline challenges associated with poorly soluble drug compounds.

To meet the industry needs, DP&FS utilizes an array of technologies including high-throughput polymer synthesis, API polymer performance screening, laboratory-scale product development, and structure-property optimization to match the polymer with the API for exceptional performance.

In addition, DP&FS operates a cGMP (Current Good Manufacturing Practices) market-development production plant to support clinical development of optimized polymers.

### **Collaborating with a Technology Leader to Solve Customer Needs**

Bend Research is the industry leader in spray-drying and formulation development for drug compounds with poor aqueous solubility.

DP&FS is an industry leader in cellulosic polymer chemistry, innovation, and manufacturing.

Dow has an exclusive collaboration with Bend Research to provide rigorous science-based spray-dried dispersion solutions and a selection of enabling cellulosics polymers to address the challenge of formulating poorly soluble drugs.

### **Enhancing Drug Solubility**

- Our AFFINISOL™ product range is tailored to address the solubilization performance requirements of each API
- Dow utilizes structure-property relationships to design distinct polymers to facilitate the required solubilization performance of an API
- Coupled with hydroxypropyl methoxycellulose products, AFFINISOL™ Hypromellose Acetate Succinate (HPMCAS) goes beyond the products commercially available today
- Dow offers sample sets which can be used to facilitate compliance with US FDA's Quality by Design (QbD) initiative
- The collaboration with Bend Research leverages polymer expertise with spray-dried dispersion (SDD) formulation and scale-up expertise
- New materials to enhance aqueous solubility of APIs through SDDs and Hot Melt Extrusion (HME) are in development

**Hypromellose Acetate Succinate Tailored to Address Drug Solubilization Needs**

Every API is unique. This is why Dow utilizes a Design of Experiment (DOE) approach to explore substituent space to offer optimized and robust performance for poorly soluble drug compounds.

Dow combines polymer structure-property relationships with small scale synthesis capability to offer an excellent product that is designed to address each APIs unique needs.


**Many Substitution Options Available**

Not all APIs can achieve a desirable balance between peak drug concentration and sustainment of supersaturated drug concentration using commercially available HPMCAS grades. Our AFFINISOL™ product range goes beyond the current commercial offering, providing more options to enhance solubilization performance.

**Substitution Level Dependence**

The APIs listed in the table on the right were used as model drugs to investigate the dependence of peak drug concentration and sustainment of supersaturated solutions on AFFINISOL™ HPMCAS substitution level in SDDs.

DRUG	TM(C)	CLOG P
Phenytoin	286	2.2
Itraconazole	166	7.1
Griseofulvin	220	2.0
Danazol	225	4.1




Each graph is based on results from internal studies from 2011-2012.

### Strong Dependence on Substitution Levels


Some APIs, such as griseofulvin and danazol showed a strong dependence on acetyl and succinyl substitution levels. Partnering with Dow to explore the entire substitution space will be beneficial for these types of APIs to find the optimum point for best performance.

25% Griseofulvin / HPMCAS SDD





- 6.6% Ac/18.7% Succ
- 10.9% Ac/9.8% Succ
- 13.5% Ac/7% Succ

25% Danazol / HPMCAS SDD



- 4.8% Ac / 13.1% Succ
- 7.8% Ac / 12.6% Succ
- 9.6% Ac / 10.5% Succ
- 12.1% Ac / 6.9% Succ





GRIS Cmax

- ≤387 500
- ≤475 000
- ≤562 500
- ≤650 000
- ≤737 500
- ≤825 000
- ≤912 500
- ≤1 000 000

GRIS AUC90

- ≤1.4e+4
- ≤1.7e+4
- ≤2e+4
- ≤2.3e+4
- ≤2.6e+4
- ≤2.9e+4
- ≤3.2e+4
- ≤3.5e+4



DAN Cmax

- ≤175
- ≤250
- ≤325
- ≤400
- ≤475
- ≤550
- ≤625
- ≤700

DAN AUC90


- ≤5500
- ≤7000
- ≤8500
- ≤10000
- ≤1.15e+4
- ≤1.3e+4
- ≤1.45e+4
- ≤1.6e+4

Each graph is based on results from internal studies from 2011-2012.


**Low Sensitivity to Substitution Levels**

Not all APIs are highly sensitive to acetyl and succinyl substitution levels. Partnering with Dow to demonstrate similar drug release performance across a wide range of substitution levels can help increase compliance with US FDA's QbD initiatives and potentially lead to better, more robust formulations. The itraconazole formulation on the right shows similar drug release behavior across a range of substitution levels. Dow's DOE approach to exploring HPMCAS substitution space will identify and lock in this range for batch to batch consistency in final product performance.


**25% Itraconazole / HPMCAS SDD**



- 4.8% Ac / 13.1% Succ    --- 10.5% Ac / 8.5% Succ
- 6.6% Ac / 18.7% Succ    ■ 10.9% Ac / 9.8% Succ
- 9.6% Ac / 10.5% Succ    ■ 12.1% Ac / 6.9% Succ



- ITZ Cmax**
- ≤100                      ■ ≤600
  - ≤200                      ■ ≤700
  - ≤300                      ■ ≤800
  - ≤400                      ■ ≤900
  - ≤500



- ITZ AUC90**
- ≤5000                    ■ ≤4.25e+4
  - ≤1.25e+4                ■ ≤5e+4
  - ≤2e+4                    ■ ≤5.75e+4
  - ≤2.75e+4                ■ ≤6.5e+4
  - ≤3.5e+4

Each graph is based on results from internal studies from 2011-2012.


**Solubilization API Trends**

- Based on Dow studies, HPMCAS materials with higher acetyl substitution and lower succinyl substitution are best for crystallization inhibition. On the other hand, materials with low acetyl and high succinyl substitution are best for lipophilic compounds.
- The substitution level of HPMCAS providing the best balance of peak drug concentration and sustainment of supersaturation may not always be a current commercially available product. In the example shown on the right, the samples plotted in dark orange, orange and yellow (10.5% Ac / 8.5% Succ; 12.1% Ac / 6.9% Succ and 13.5% Ac / 7% Succ) represent materials that are within the substitution ranges of current commercial products. The sample mapped out in dark red (10.9% Ac / 9.8% Succ) provides a higher peak drug concentration and better maintenance of elevated concentration for extended periods of time compared to any of the materials with substitution levels within current grades.


**Innovative Solutions in the Making**

Dow continues to invest in developing expanded AFFINISOL™ polymer solutions, both cellulosics and non-cellulosics-based, to address poorly soluble drug challenges and improvements to the solid dispersion as well as hot melt extrusion manufacturing processes.


**25% Phenytoin / HPMCAS SDD**



- 10.5% Ac / 8.5% Succ
- 12.1% Ac / 6.9% Succ
- 10.9% Ac / 9.8% Succ
- 13.5% Ac / 7% Succ



- PHY Cmax
- ≤300
  - ≤350
  - ≤400
  - ≤450
  - ≤500
  - ≤550
  - ≤600
  - ≤650
  - ≤700
  - ≤700



- PHY AUC90
- ≤2e+4
  - ≤2.25e+4
  - ≤2.5e+4
  - ≤2.75e+4
  - ≤3e+4
  - ≤3.25e+4
  - >3.25e+4

Each graph is based on results from internal studies from 2011-2012.

---

North America	+1 800 447 4369
Europe, Middle East, Africa	+31 11 567 2626
Pacific	+60 3 7965 5392
Latin America	+55 11 5184 8722

**[www.dowpharmaandfood.com](http://www.dowpharmaandfood.com)**

---

®™Trademark of The Dow Chemical Company ("Dow") or an affiliated company of Dow • Form No. 198-02291 - 10/13 EST

Dow requests that customers considering use of Dow products in medical applications notify Dow so that appropriate assessments may be conducted. Dow has a Corporate Medical Application Policy in place that guides the use of Dow products in potential new pharmaceutical and medical device uses. Dow reviews all new applications/uses according to this Medical Application Policy to determine if the use is appropriate for Dow materials. Dow does not endorse or claim suitability of its products for specific medical applications. It is the responsibility of the medical device or pharmaceutical manufacturer to determine that the Dow product is safe, lawful, and technically suitable for the intended use. DOW MAKES NO WARRANTIES, EXPRESS OR IMPLIED, CONCERNING THE SUITABILITY OF ANY DOW PRODUCT FOR USE IN MEDICAL APPLICATIONS.

NOTICE: No freedom from infringement of any patent owned by Dow or others is to be inferred. Because use conditions and applicable laws may differ from one location to another and may change with time, Customer is responsible for determining whether products and the information in this document are appropriate for Customer's use and for ensuring that Customer's workplace and disposal practices are in compliance with applicable laws and other government enactments. The product shown in this literature may not be available for sale and/or available in all geographies where Dow is represented. The claims made may not have been approved for use in all countries. Dow assumes no obligation or liability for the information in this document. References to "Dow" or the "Company" mean the Dow legal entity selling the products to Customer unless otherwise expressly noted. NO WARRANTIES ARE GIVEN; ALL IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE ARE EXPRESSLY EXCLUDED.